Search research articles
Contact Us
Filters
Showing results (41-50 of 440) with videos related to
Page
of 44
Sort By:
Onkologie
|
April 8, 2006
Proteasome inhibition: novel therapy for multiple myeloma
Jonathan L Kaufman, Sagar Lonial
Oncology (Williston Park, N.Y.)
|
November 29, 2013
Non-secretory myeloma: a clinician's guide
Sagar Lonial, Jonathan L Kaufman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma
Craig C Hofmeister, Sagar Lonial
Blood
|
March 12, 2008
Eliminating the complete response penalty from myeloma response assessment
Sagar Lonial, Morie A Gertz
Oncology (Williston Park, N.Y.)
|
January 17, 2017
Insights Into the Appropriate Use of New Antimyeloma Therapies
Jonathan L Kaufman, Sagar Lonial
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Is Maintenance Therapy for Everyone?
Ajay K Nooka, Sagar Lonial
Leukemia & Lymphoma
|
February 18, 2011
Putting the E (evidence) in a new Era for myeloma
Jonathan L Kaufman, Sagar Lonial
Journal of Oncology Practice
|
April 14, 2016
Myeloma Is Not a Single Disease
Sagar Lonial, Ajay K Nooka
Cancer Journal (Sudbury, Mass.)
|
January 30, 2019
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Ajay K Nooka, Sagar Lonial
Expert Opinion on Biological Therapy
|
April 19, 2005
Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity
Jason J Everly, Sagar Lonial
Page
of 44
Search research articles
Search
Showing results (41-50 of 440) with videos related to
Sort By:
Page
of 44
Onkologie
|
April 8, 2006
Proteasome inhibition: novel therapy for multiple myeloma
Jonathan L Kaufman, Sagar Lonial
Oncology (Williston Park, N.Y.)
|
November 29, 2013
Non-secretory myeloma: a clinician's guide
Sagar Lonial, Jonathan L Kaufman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 22, 2016
How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma
Craig C Hofmeister, Sagar Lonial
Blood
|
March 12, 2008
Eliminating the complete response penalty from myeloma response assessment
Sagar Lonial, Morie A Gertz
Oncology (Williston Park, N.Y.)
|
January 17, 2017
Insights Into the Appropriate Use of New Antimyeloma Therapies
Jonathan L Kaufman, Sagar Lonial
Clinical Lymphoma, Myeloma & Leukemia
|
August 14, 2016
Is Maintenance Therapy for Everyone?
Ajay K Nooka, Sagar Lonial
Leukemia & Lymphoma
|
February 18, 2011
Putting the E (evidence) in a new Era for myeloma
Jonathan L Kaufman, Sagar Lonial
Journal of Oncology Practice
|
April 14, 2016
Myeloma Is Not a Single Disease
Sagar Lonial, Ajay K Nooka
Cancer Journal (Sudbury, Mass.)
|
January 30, 2019
Mechanism of Action and Novel IMiD-Based Compounds and Combinations in Multiple Myeloma
Ajay K Nooka, Sagar Lonial
Expert Opinion on Biological Therapy
|
April 19, 2005
Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity
Jason J Everly, Sagar Lonial
Page
of 44